Synthesis and in vitro evaluation of novel rhodanine derivatives as potential cholinesterase inhibitors

Bioorganic Chemistry

Volumn 68, Issue , 2016, Pages 23-29

  Krátký, Martin ^a   Štěpánková, Šárka ^b   Vorčáková, Katarína ^b   Vinšová, Jarmila ^a  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^b UNIVERSITY OF PARDUBICE   (Czech Republic)

Author keywords

2 (4 Oxo 2 thioxothiazolidin 3 yl)acetic acid; Acetylcholinesterase; Butyrylcholinesterase; Enzyme inhibition; Rhodanine

Indexed keywords

CHOLINESTERASE INHIBITOR; RHODANINE DERIVATIVE; RIVASTIGMINE; UNCLASSIFIED DRUG; ACETYLCHOLINESTERASE; CHOLINESTERASE; RHODANINE;

AMIDATION; ARTICLE; DRUG ACTIVITY; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; ESTERIFICATION; IC50; IN VITRO STUDY; PRIORITY JOURNAL; ANIMAL; BLOOD; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; ELECTROPHORUS; HORSE; METABOLISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ACETYLCHOLINESTERASE; ANIMALS; BUTYRYLCHOLINESTERASE; CHOLINESTERASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHORUS; HORSES; MOLECULAR STRUCTURE; RHODANINE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84978805250     PISSN: 00452068     EISSN: 10902120     Source Type: Journal    
DOI: 10.1016/j.bioorg.2016.07.004     Document Type: Article

References (38)

1. Tomasic, T., Masic, L.P., Rhodanine as a privileged scaffold in drug discovery. Curr. Med. Chem. 16 (2009), 1596–1629.
2. Rana, A.M., Desai, K.R., Jauhari, S., Rhodanine-based biologically active molecules: synthesis, characterization, and biological evaluation. Res. Chem. Intermed. 40 (2014), 761–777.
3. Zvarec, O., Polyak, S.W., Tieu, W., Kuan, K., Daim, H., Pedersen, D.S., Morona, R., Zhang, L., Booker, G.W., Abell, A.D., 5-Benzylidenerhodanine and 5-benzylidene-2-4-thiazolidinedione based antibacterials. Bioorg. Med. Chem. Lett. 22 (2012), 2720–2722.
4. Miao, J., Zheng, C.J., Sun, L.P., Song, M.X., Xu, L.L., Piao, H.R., Synthesis and potential antibacterial activity of new rhodanine-3-acetic acid derivatives. Med. Chem. Res. 22 (2013), 4125–4132.
5. Chen, Z.H., Zheng, C.J., Sun, L.P., Piao, H.R., Synthesis of new chalcone derivatives containing a rhodanine-3-acetic acid moiety with potential anti-bacterial activity. Eur. J. Med. Chem. 45 (2010), 5739–5743.
6. Chauhan, K., Sharma, M., Singh, P., Kumar, V., Shukla, P.K., Siddiqic, M.I., Chauhan, P.M.S., Discovery of a new class of dithiocarbamates and rhodanine scaffolds as potent antifungal agents: synthesis, biology and molecular docking. Med. Chem. Commun. 3 (2012), 1104–1110.
7. Dolezel, J., Hirsova, P., Opletalova, V., Dohnal, J., Vejsova, M., Kunes, J., Jampilek, J., Rhodanineacetic acid derivatives as potential drugs: preparation, hydrophobic properties and antifungal activity of (5-arylalkylidene-4-oxo-2-thioxo-1,3-thiazolidin-3-yl)acetic acids. Molecules 14 (2009), 4197–4212.
8. Talele, T.T., Arora, P., Kulkarni, S.S., Patel, M.R., Singh, S., Chudayeu, M., Kaushik-Basu, N., Structure-based virtual screening, synthesis and SAR of novel inhibitors of hepatitis C virus NS5B polymerase. Bioorg. Med. Chem. 18 (2010), 4630–4638.
9. Min, G., Lee, S.K., Kim, H.N., Han, Y.M., Lee, R.H., Jeong, D.G., Han, D.C., Kwon, B.M., Rhodanine-based PRL-3 inhibitors blocked the migration and invasion of metastatic cancer cells. Bioorg. Med. Chem. Lett. 23 (2013), 3769–3774.
10. Shafii, N., Khoobi, M., Amini, M., Sakhteman, A., Nadri, H., Moradi, A., Emami, S., Moghadam, E.S., Foroumadi, A., Shafiee, A., Synthesis and biological evaluation of 5-benzylidenerhodanine-3-acetic acid derivatives as AChE and 15-LOX inhibitors. J. Enzyme Inhib. Med. Chem. 30 (2015), 389–395.
11. Maccari, R., Del Corso, A., Giglio, M., Moschini, R., Mura, U., Ottana, R., In vitro evaluation of 5-arylidene-2-thioxo-4-thiazolidinones active as aldose reductase inhibitors. Bioorg. Med. Chem. Lett. 21 (2011), 200–203.
12. Zeiger, E., Anderson, B., Haworth, S., Lawlor, T., Mortelmans, K., Speck, W., Salmonella mutagenicity tests: III. Results from the testing of 255 chemicals. Environ. Mutagen. 9 (1987), 1–60.
13. Tomasic, T., Masic, L.P., Rhodanine as a scaffold in drug discovery: a critical review of its biological activities and mechanisms of target modulation. Expert Opin. Drug Discov. 7 (2012), 549–560.
14. Reitz, C., Mayeux, R., Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem. Pharmacol. 88 (2014), 640–651.
15. Singh, M., Kaur, M., Kukreja, H., Chugh, R., Silakari, O., Singh, D., Acetylcholinesterase inhibitors as Alzheimer therapy: from nerve toxins to neuroprotection. Eur. J. Med. Chem. 70 (2013), 165–188.
16. Colovic, M.B., Krstic, D.Z., Lazarevic-Pasti, T.D., Bondzic, A.M., Vasic, V.M., Acetylcholinesterase Inhibitors: pharmacology and toxicology. Curr. Neuropharmacol. 11 (2013), 315–335.
17. Cummings, J.L., Morstorf, T., Zhong, K., Alzheimer's disease drug-development pipeline: few candidates, frequent failures. Alzheimer's Res. Ther., 6, 2014 Article Number 37.
18. Martinez, A., Alonso, M., Castro, A., Dorronsoro, I., Gelpi, J.L., Luque, F.J., Perez, C., Moreno, F.J., SAR and 3D-QSAR studies on thiadiazolidinone derivatives: exploration of structural requirements for glycogen synthase kinase 3 inhibitors. J. Med. Chem. 48 (2005), 7103–7112.
19. Kim, H.J., Choo, H., Cho, Y.S., No, K.T., Pae, A.N., Novel GSK-3 beta inhibitors from sequential virtual screening. Bioorg. Med. Chem. 16 (2008), 636–643.
20. Bulic, B., Pickhardt, M., Khlistunova, I., Biernat, J., Mandelkow, E.M., Mandelkow, E., Waldmann, H., Rhodanine-based tau aggregation inhibitors in cell models of tauopathy. Angew. Chem. Int. Ed. 46 (2007), 9215–9219.
21. Schafer, K.N., Cisek, K., Huseby, C.J., Chang, E., Kuret, J., Structural determinants of tau aggregation inhibitor potency. J. Biol. Chem. 288 (2013), 32599–32611.
22. Vinšová, J., Krátký, M., Komlóová, M., Dadapeer, E., Štěpánková, Š., Vorčáková, K., Stolaříková, J., Diethyl 2-(phenylcarbamoyl)phenyl phosphorothioates: synthesis, antimycobacterial activity and cholinesterase inhibition. Molecules 19 (2014), 7152–7168.
23. Krátký, M., Štepánková, Š., Vorčáková, K., Vinšová, J., Salicylanilide diethyl phosphates as cholinesterases inhibitors. Bioorg. Chem. 58 (2015), 48–52.
24. Krátký, M., Štěpánková, Š., Vorčáková, K., Švarcová, M., Vinšová, J., Novel cholinesterase inhibitors based on O-aromatic N,N-disubstituted carbamates and thiocarbamates. Molecules 21 (2016), 191–200.
25. Rijkers, D.T.S., Adams, H.P.H.M., Hemker, H.C., Tesserl, G.I., A convenient synthesis of amino acid p-nitroanilides; synthons in the synthesis of protease substrates. Tetrahedron 51 (1995), 11235–11250.
26. Ou, S.Y., Kwok, K.C., Wang, Y., Bao, H.Y., An improved method to determine SH and [Formula presented] group content in soymilk protein. Food Chem. 88 (2004), 317–320.
27. Riaz, S., Khan, I.U., Bajda, M., Ashraf, M., Qurat-ul-Ain, Shaukat, A., Rehman, T.U., Mutahir, S., Hussain, S., Mustafa, G., Yar, M., Pyridine sulfonamide as a small key organic molecule for the potential treatment of type-II diabetes mellitus and Alzheimer's disease: in vitro studies against yeast a-glucosidase, acetylcholinesterase and butyrylcholinesterase. Bioorg. Chem. 63 (2015), 64–71.
28. Rahim, F., Javed, M.T., Ullah, H., Wadood, A., Taha, M., Ashraf, M., Qurat-ul-Ain, Khan, M.A., Khan, F., Mirza, S., Khan, K.M., Synthesis, molecular docking, acetylcholinesterase and butyrylcholinesterase inhibitory potential of thiazole analogs as new inhibitors for Alzheimer disease. Bioorg. Chem. 62 (2015), 106–116.
29. Heng, S., Tieu, W., Hautmann, S., Kuan, K., Pedersen, D.S., Pietsch, M., Gütschow, M., Abell, A.D., New cholesterol esterase inhibitors based on rhodanine and thiazolidinedione scaffolds. Bioorg. Med. Chem. 19 (2011), 7453–7463.
30. Leo, A., Hansch, C., Elkins, D., Partition coefficients and their uses. Chem. Rev. 71 (1971), 525–616.
31. Lipinski, C.A., Lombardo, F., Dominy, B.W., Feeney, P.J., Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46 (2001), 3–26.
32. Lipinski, C.A., Lead- and drug-like compounds: the rule-of-five revolution. Drug Discov. Today: Technol. 1 (2004), 337–341.
33. Hitchcock, S.A., Pennington, L.D., Structure-brain exposure relationships. J. Med. Chem. 49 (2006), 7559–7583.
34. Sinko, G., Calic, M., Bosak, A., Kovarik, Z., Limitation of the Ellman method: cholinesterase activity measurement in the presence of oximes. Anal. Biochem. 370 (2007), 223–227.
35. Zdrazilova, P., Stepankova, S., Komers, K., Ventura, K., Cegan, A., Half-inhibition concentrations of new cholinesterase inhibitors. Z. Naturforsch. C 59 (2004), 293–296.
36. Berthod, A., Carda-Broch, S., Determination of liquid–liquid partition coefficients by separation methods. J. Chromatogr. A 1037 (2004), 3–14.
37. Sangster, J., Octanol-water partition coefficients of simple organic compounds. J. Phys. Chem. Ref. Data 18 (1989), 1111–1229.
38. OECD, OECD Guideline for the Testing of Chemicals. < http://www.oecd.org/chemicalsafety/risk-assessment/1948169.pdf>, 1995 (accessed 12.04.15).